Search
Infliximab
go.drugbank.com/drugs/DB00065ApprovedInvestigationalInfliximab was first approved by the FDA in 1998 under the market name Remicade as an intravenous injection. … Inflectra, a first biosimilar drug product, was approved in 2016. In December 2017, Ixifi, a second biosimilar that was developed by Pfizer, was granted approval by the FDA.
Cobimetinib
go.drugbank.com/drugs/DB05239ApprovedInvestigationalIt has been approved in Switzerland and the US, in combination with vemurafenib for the treatment of patients with unresectable or metastatic BRAF V600 mutation-positive melanoma. … Cobimetinib is an orally active, potent and highly selective small molecule inhibiting mitogen-activated protein kinase kinase 1 (MAP2K1 or MEK1), and central components of the RAS/RAF/MEK/ERK signal transduction
Andexanet alfa
go.drugbank.com/drugs/DB14562ApprovedIt was developed by Portola Pharmaceuticals and was approved in in May 2018. … Rivaroxaban and apixaban are Factor Xa inhibitors that promote anticoagulation in situations where blood clotting is unfavourable, such as in deep vein thrombosis and pulmonary embolism.
Mequinol
go.drugbank.com/drugs/DB09516ApprovedWithdrawnIt is used as an inhibitor for acrylic monomers and acrylonitirles, as a stabilizer for chlorinated hydrocarbons and ethyl cellulose, as an ultraviolet inhibitor, as a chemical intermediate in the manufacture … It is found as an active ingredient in topical drugs used for skin depigmentation indicated for the treatment of solar lentigines.
Tamoxifen
go.drugbank.com/drugs/DB00675ApprovedInvestigationalTamoxifen is a non-steroidal antiestrogen used to treat estrogen receptor positive breast cancers as well as prevent the incidence of breast cancer in high risk populations. … [A1026] Tamoxifen was granted FDA approval on 30 December 1977.[L7799]
Mineral oil
go.drugbank.com/drugs/DB11057ApprovedInvestigationalVet approvedIt is also used as a mild laxative for human or veterinary uses. … Unrefined or mildly treated mineral oils are classified as Group 3 carcinogens by the World Health Organizations, as chronic exposure to these aromatics including alkylated polycyclic aromatic compounds
Adapalene
go.drugbank.com/drugs/DB00210ApprovedInvestigational[A193518] Differin®, produced by Galderma Labs, was first granted FDA approval on May 31st, 1996, as a 0.1% adapalene topical solution. … Differin was later made available as 0.1% gel, cream, or lotion, or 0.3% gel products. On December 8th, 2008, Galderma Labs gained FDA approval for Epiduo®, a 0.1% adapalene, 2.5% BPO combination gel.
Lanreotide
go.drugbank.com/drugs/DB06791ApprovedInvestigationalLanreotide is manufactured by the company, _Ipsen Pharmaceuticals_ as lanreotide acetate, and marketed as _Somatuline_. … Lanreotide was first approved for use in the United States by the FDA on August 30, 2007.
Atoltivimab
go.drugbank.com/drugs/DB15898ApprovedInvestigationalINMAZEB™ is produced by Regeneron Pharmaceuticals and was granted FDA approval on October 14, 2020.[L17320] … [A222078] INMAZEB™, formerly referred to as REGN-EB3, combines the three humanized IgG1κ mAbs Atoltivimab (REGN 3470), [Odesivimab] (REGN 3471), and [Maftivimab] (REGN 3479) in equimolar proportions
Pasireotide
go.drugbank.com/drugs/DB06663ApprovedInvestigationalIt is marketed as a diaspartate salt called Signifor, which is used in the treatment of Cushing's disease.